Ketamine therapy among patients with treatment-resistant depression: a double-blind, randomised, controlled trial (The KADS Trial) - Clinical Trial Protocol & Statistical Analysis Plan

Abstract

The KADS Trial is a randomised controlled trial which aims to determine whether a 4-week course of subcutaneous ketamine is an efficacious therapy for treatment-resistant depression. This registration contains the study's clinical trial protocol, as well as the statistical analysis plan for the primary publication relating to the study's randomised controlled trial phase. The main registration for this trial is available on the Australian New Zealand Clinical Trials Registry (www.anzctr.org.au; registration number ACTRN12616001096448).

Topics & conditions

Detected automatically by Psychedelic Commons from the title and abstract, not labels from the source. They may be incomplete.

Keywords